Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-TUMOR, ANTI-BACTERIAL AND/OR ANTI-VIRAL APPLICATIONS OF CTLA4IG AND DERIVATIVES THEREOF.
Document Type and Number:
WIPO Patent Application WO/2010/091542
Kind Code:
A1
Abstract:
The present invention relates to the use of CTLA4Ig or CTLA4Ig derivatives in the preparation of anti-tumor, anti-bacterial and/or anti-viral drugs. It was found by the inventor that CTLA4Ig or CTLA4Ig derivatives significantly enhanced the cytotoxicity of NK cells by increasing the expression of the activating receptors (such as NKG2D, NKp44 and the likes) on NK cell surface, thereby they could be used for the anti-tumor, anti-bacterial and/or anti-viral treatment.

Inventors:
WU JUN (CN)
LUO GAOXING (CN)
HE WEIFENG (CN)
Application Number:
PCT/CN2009/001590
Publication Date:
August 19, 2010
Filing Date:
December 30, 2009
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SOUTHWEST HOSPITAL CHONGQING (CN)
WU JUN (CN)
LUO GAOXING (CN)
HE WEIFENG (CN)
International Classes:
A61K38/17; A61P31/04; A61P31/12; A61P35/00
Foreign References:
CN1842541A2006-10-04
Other References:
GALEA-LAURI J ET AL.: "Expression of a Variant of CD28 on a Subpopulation of Human NK Cells: Implications for B7-Mediated Stimulation of NK Cells.", J IMMUNOL., vol. 163, 1999, pages 62 - 70, XP002286442
HERVEY PS ET AL.: "Abatacept.", BIODRUGS., vol. 20, no. 1, 2006, pages 53 - 61
LARSEN CP ET AL.: "Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.", AM J TRANSPLANT., vol. 5, no. 3, 2005, pages 443 - 453, XP002393471, DOI: doi:10.1111/j.1600-6143.2005.00749.x
Attorney, Agent or Firm:
CHINA SCIENCE PATENT & TRADEMARK AGENT LTD (Bldg. BTsinghua Tongfang Hi-Tech Plaza,No.1, Wangzhuang Roa, Haidian District Beijing 3, CN)
Download PDF: